Atai Life Sciences NV Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ATAI Life Sciences N.V. reported a reduction in its beneficial ownership of COMPASS Pathways plc to 6.0% through recent open market sales.
NASDAQ
SCHEDULE 13D/A: Apeiron Group Boosts ATAI Stake to 24% Amid Offering
Apeiron Investment Group and related entities increased their beneficial ownership in ATAI Life Sciences N.V. to 24.0% following a share conversion and a new lock-up agreement.
NASDAQ
Apeiron Investment Group and affiliates increased their beneficial ownership in ATAI Life Sciences N.V. to 24.3% through a $19 million PIPE financing.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Apeiron Investment Group Increases Stake in ATAI Life Sciences, Secures Board Representation and Voting Rights
Apeiron Investment Group and its affiliates have increased their beneficial ownership in ATAI Life Sciences N.V. to 22.2%, securing significant voting rights, board representation, and registration rights through new agreements.
NASDAQ
SCHEDULE 13D/A: ATAI Life Sciences Updates Stake in COMPASS Pathways to 7.5%
ATAI Life Sciences N.V. and its subsidiary ATAI Life Sciences AG have filed an Amendment No. 4 to Schedule 13D, disclosing a beneficial ownership of 7.5% in COMPASS Pathways plc as of March 5, 2025.
NASDAQ
SCHEDULE 13D: Apeiron Investment Group and Christian Angermayer Boost Stake in ATAI Life Sciences to 22.7% Following $55 Million Offering
Apeiron Investment Group and its controlling shareholder Christian Angermayer have significantly increased their beneficial ownership in ATAI Life Sciences N.V. to 22.7% following the company's recent $55 million registered offering.